ReviewIranian journal of biotechnology2025
Aptamers in Combination Therapies for Enhanced Radiosensitization in Cancer.
Review in Iranian journal of biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Enzyme-Mediated Precipitation of Heavy Metals Using Urease Extracted fromIranian journal of biotechnology · 2026Article
- Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization.BioImpacts : BI · 2025Review
- Enhancing Radiotherapy for Hypoxic Tumors: Integrative Strategies Using Bacteria and Nanoparticles.IET nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review explores the emerging role of aptamers in enhancing radiotherapy (RT) efficacy through their ability to target tumor sites with high specificity. Cancer, a complex disease, involves uncontrolled cell growth, and radiosensitization refers to the process of making cancer cells more sensitive to radiation therapy. As versatile carriers, aptamers facilitate the delivery of radiosensitizing agents such as nanoparticles, siRNAs, and therapeutic molecules. These conjugates modulate cell signaling, enhance free radical production, and influence the tumor microenvironment (TME) via immunomodulatory mechanisms, thereby indirectly increasing tumor radiosensitivity. Key findings highlight aptamer-based strategies for disrupting critical pathways, boosting immune responses, and overcoming tumor resistance. Advances in multi-agent and liposomal delivery systems further underscore their potential to address tumor heterogeneity and immune evasion. This review consolidates recent developments, emphasizing aptamers' role as precise delivery vehicles for optimizing RT outcomes and advancing cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.